School trip coming up this weekend.
A list to make, people to inform, check of medication supply and taking care of some food items like snacks.
School counselor, school nurse, student advisor and Solange are involved and will take care that the trip will be safe.
While mentioning to the counselor that the story lines behind the allergies have much in common with a fairy tale, though a rather dramatic one. The deadly peanut kiss. So no kissing for the moment is the best solution to prevent any fatal ending of the fairy. True but not a very reliable thought. No peanuts during the trip is a better option. This brings us back again into the same discussions. Main topic: is it fair to ask from classmates not to bring any of their favorite food because of the fact that somebody happens to be deadly allergic?!
Research learns that young people, adolescents rather prefer not to share any of their 'weaknesses' with their peers. Researchers say : most young people never mention 'being allergic' to most of their friends. Being allergic is still too often a taboo. To avoid that adolescents with allergies will not join in school trips and will be disconnected from social networks, we need to act. Honest information, the set up of a clear policy about allergies, discussion between peers are all tools in a serious approach to the patient and the involved environment.
http://www.living.without.com 'Adolescents and Anaphylaxis'
Peanut Allergy therapy tested
“Doctors in Cambridge believe they may soon have a cure for peanut allergies,” BBC News reported. It said the researchers believe a treatment could be available in two to three years.
“Doctors in Cambridge believe they may soon have a cure for peanut allergies,” BBC News reported. It said the researchers believe a treatment could be available in two to three years.
The news is based on a largerandomised controlled trial (RCT)that is about to start. The research follows a successful pilot study of a treatment called peanut oral immunotherapy (OIT), in which allergic children are repeatedly exposed to strictly controlled doses of peanut protein. Its success so far shows that it has good potential and the results from the upcoming RCT are greatly anticipated.
However, it is vitally important that no attempts are made to replicate the treatment at home as severe allergic reactions can be fatal. If the treatment works it will be offered to children with peanut allergies in the safe and controlled manner that will be necessary for its success.
It should be noted that this treatment is not a cure, and several unknowns need to be addressed, including whether this treatment works in adults and the nature of its long-term effects in children.
What is the basis for these current reports?
The news stories are based on research carried out by Dr Andrew Clark and colleagues from Addenbrooke’s Hospital in Cambridge. The team has had success in previous pilot studies with a technique known as peanut oral immunotherapy. This treatment aims to desensitise the immune system to the allergen (the substance that usually causes an allergic response) by gradually increasing its exposure.
A £1 million grant has now been given to Dr Clark and his team by the National Institute for Health Research, to carry out a larger RCT in more than 100 children with peanut allergies.
The results of the pilot studies and the new trial were presented by Dr Clark at the annual meeting of the American Association for the Advancement of Science.
Has this therapy been tested before?
Dr Clark announced the results of a previous trial in 23 children between 7 and 17 years of age. These children were given a very small amount of peanut flour in yoghurt every day, and the amount was increased every two weeks until the children could eat five peanuts a day. Most of the children had some reactions when the dose was increased, including oral itching and abdominal pain. However, by the end of the trial, 21 of the 23 children could eat five peanuts a day and one could eat two peanuts a day.
More information about peanut oral immunotherapy is available from another pilot study published in February 2009. This trial, in four boys with suspected peanut allergy, was covered by Behind the Headlines. Each boy had an allergic response to between 5 and 50mg of peanut protein (a fraction of the approximately 200mg present in a whole peanut). The boys were exposed to increasing daily doses of peanut flour, up to a maximum of 800mg of peanut protein. Each boy was given a personalised dosing schedule depending on their initial tolerance levels. After six weeks of carefully tailored daily treatment, all four boys were able to eat up to 800mg of peanut protein without any serious adverse effects.
More research is needed into this treatment, and the researchers have begun a larger RCT - the best way to establish the effectiveness of a treatment.
What is the new trial?
Dr Clark presented the plans for a larger study (an RCT) during his presentation to the AAAS conference. There is only limited information publicly available about the trial, but it is known that it is a large controlled trial involving 104 participants who will be randomised to peanut OIT or no treatment. The trial will cost £1 million, sponsored by the Department of Health’s Institute of Health Research, and will run for three years. Children will be given the equivalent of up to five nuts per day in a carefully controlled dosing schedule that depends on their initial tolerance.
Are peanut allergies common?
Dr Clark reports that between 1997 and 2007 there was an 18% increase in childhood food allergy. According to Clark, approximately 1 in 50 children have a nut allergy and 10% of reactions to peanuts will be severe ones. Aside from potentially fatal reactions and the fear of them, children with peanut allergies also experience restricted food choices that can affect their social behaviour. While most children will outgrow allergies to milk, eggs, soya and wheat, peanut allergies are more persistent and an estimated 80% of children remain allergic to peanuts for the rest of their lives.
Many people believe that deaths from food allergies are common and the NHS highlights this as a frequently held misconception. This may be due to the fact that the deaths receive a lot of media coverage when they do occur, but in fact, death from food allergies is very rare. For instance, there were six deaths recorded as a result of food allergies in 2008.
Conclusion
The previous success of this treatment shows that it has good potential for treating children with peanut allergy, and the results from the upcoming RCT are anticipated with great interest. Its strong study design will provide robust answers to questions about the efficacy and safety of this treatment for children with allergies.
It should be noted that this treatment is not a cure, and several unknowns need to be addressed, including whether this treatment works in adults and the nature of its long-term effects in children.
Dr Clark said in The Times: “I think in two or three years time we will be in a position where we have a treatment that works, but we are still working on a long-term cure.
“It’s likely to be a treatment that lasts at least two or three years, and we hope that once that's over we can withdraw the treatment and maintain long-term tolerance, but we need a long-term study to find out.”
Most importantly, these trials are taking place under carefully controlled conditions and in no way should attempts be made to replicate them at home. Several safety precautions are in place should any of the children have an allergic reaction, and the amount of peanut given is carefully measured for each child’s own personal initial tolerance levels.
The short period of two to three years until a working treatment is encouraging. Until it is available, parents should continue to manage their children’s exposure as they have been doing. Peanut allergies can be successfully managed by vigilantly avoiding exposure and by treating accidental exposures with appropriate medications – antihistamines or adrenaline as advised by your doctor.





